Temporary suspension in the US
On March 22, 2010, the detection of DNA from porcine circovirus types 1 and 2 within RotaTeq and Rotarix prompted the FDA to suspend the use of rotavirus vaccines while conducting an investigation the finding of DNA from porcine circovirus-1 (PCV1) in the vaccine in collaboration with the 12 members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). On May 6, 2010, the FDA announced its decision to revoke the suspension, stating that porcine circovirus types 1 and 2 pose no safety risks in humans and concluded that health risks involved did not offset the benefits of the vaccination. In May 2010 the suspension of the Rotarix vaccine was lifted. Research
Doctors Without Borders (MSF) developed a heat-stable version named BRV-PV. Phase 3 of the clinical trials were completed in Niger on December 31, 2020.The vaccine has been associated with lower rates of type 1 diabetes. References
Further reading
Cortese MM, Parashar UD (February 2009). "Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR Recomm Rep. 58 (RR-2): 1–25. PMID 19194371. External links
"Rotavirus Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 2019-10-25. Rotavirus, Vaccine Resource Library
Rotavirus ROTA Council
Rotavirus Vaccines at the US National Library of Medicine Medical Subject Headings (MeSH)
Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.It was approved for medical use in the United States in September 2021. Medical uses
Atogepant is indicated for the preventive treatment of episodic migraine in adults. Research
A study found that atogepant reduced the number of migraine days over twelve weeks. References
External links
"Atogepant". Drug Information Portal. U.S. National Library of Medicine.